Medication info
Jadiflozin M Tablet 5/850 mg (Empagliflozin, Metformin Hydrochloride)

Jadiflozin M Tablet 5/850 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Youngpoong Pharmaceutical Co., Ltd.
Appearance
White, oval-shaped film-coated tablet with a yellow tint and double convex sides.
Packaging
10 tablets/box (10 tablets/PTP×1), 60 tablets/box (10 tablets/PTP×6), 30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202201355 · Approved 2022.04.04 · Insurance code 661905710

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each active ingredient: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Ingredients

Manufacturer
Youngpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Blood sugar control issues in patients with type 2 diabetes
  • insufficiently controlled blood sugar levels
  • cardiovascular disease.
View approved original text

This medication helps improve blood sugar control in adult patients with type 2 diabetes using a combination of empagliflozin and metformin. It is given as an adjunct to diet and exercise for patients whose blood sugar is not adequately controlled, and it is especially effective in patients with type 2 diabetes. Additionally, for patients with cardiovascular disease, it is necessary to refer to expert guidelines regarding this drug's impact on cardiovascular events. This medication is used to improve blood sugar control and assist in diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each active ingredient: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who do not achieve adequate glycemic control with metformin alone or in combination with other medicines, such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient’s current dose of metformin. If empagliflozin 10 mg (total daily dose) is well tolerated but additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive the same doses of empagliflozin and metformin that they were taking previously. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If a dose of this medicine is missed, take it as soon as remembered. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should be initiated with the individual single-ingredient products, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use 2. Patients Who Must Not Take This Medicine, item 2)). Elderly patients In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.

Precautions

This medication assists in controlling blood sugar. However, there are several important precautions to consider when taking it. First, this medication may cause a rare side effect known as severe lactic acidosis. Lactic acidosis can become a dangerous condition if too much lactic acid accumulates in the body, so it is particularly important to monitor your condition while taking this medication. Additionally, there is a risk of hypoglycemia when taken with insulin or other diabetes medications, so blood sugar levels should be checked frequently. This medication should not be used in patients with moderate to severe renal impairment, acute cardiac issues, severe infections, or dehydration. Furthermore, it is considered safe for pregnant or breastfeeding women not to take this medication. Regular renal function tests should be done before starting the medication and during treatment, and the medication should be discontinued if renal function deteriorates. This medication may have side effects such as gastrointestinal disturbances, urinary infections, genital infections, and increased urination. Women may experience genital infections more frequently, so consult a physician immediately if symptoms occur. Additionally, this medication can cause fluid volume loss, hence caution is needed when prescribing it to patients at risk of dehydration or hypotension. Alcohol consumption can increase the risk of lactic acidosis, so it is recommended not to consume excessive alcohol while on this medication. If undergoing surgery or tests utilizing iodinated contrast, the medication should be discontinued for a certain period and can be resumed after renal function has normalized. This medication may reduce vitamin B12 levels, so it is advisable to monitor vitamin B12 levels during prolonged use. Elderly patients or those with diminished renal function should use this medication with particular caution, starting with the minimum effective dose is recommended. Finally, inform healthcare professionals immediately about any symptoms of hypoglycemia or any unusual symptoms while taking this medication.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 182 more
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vulvovaginitis
  • vulvar vaginitis
  • balanitis
  • perineal gangrene
  • decreased fluid volume
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • vitamin B12 decrease and deficiency
  • ketoacidosis
  • lactic acidosis
  • headache
  • dizziness
  • fever
  • weakness
  • chest discomfort
  • chest pain
  • vascular stent stenosis
  • vascular stent thrombosis
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • hyperglycemia
  • dyslipidemia
  • insomnia
  • anxiety
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • diabetic foot
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • urolithiasis
  • hematuria
  • renal mass
  • urinary retention
  • urinary abnormalities
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • cervical inflammation
  • scrotal pain
  • vaginal discharge
  • position-related dizziness
  • sensory impairment
  • altered perception
  • amnesia
  • carotid artery stenosis
  • diabetic neuropathy
  • facial paralysis
  • intracranial aneurysm
  • memory abnormalities
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory disorders
  • drowsiness
  • CNS-origin vertigo
  • fatigue
  • peripheral edema
  • facial swelling
  • peripheral swelling
  • chills
  • strange sensation
  • edema
  • pain
  • pain at the puncture site
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine erythrocytes
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • unstable angina
  • hypertension
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery obstructive disease
  • anxiety
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • position-related vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • constipation
  • diarrhea
  • dyspepsia
  • abdominal pain
  • nausea
  • gastritis
  • gastrointestinal disturbance
  • nasopharyngitis
  • herpes zoster
  • dizziness
  • headache
  • chest discomfort
  • chest pain
  • weakness
  • weight loss
  • vulvar pruritus
  • genital pruritus
  • dyslipidemia
  • hyperglycemia
  • back pain
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • glaucoma
  • macular fibrosis
  • ocular discomfort
  • conjunctival injection
  • pathological myopia
  • retinal detachment
  • retinal crystal deposits
  • retinal vein occlusion
  • proliferative retinal detachment
  • eyelid edema
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • productive cough
  • allergic rhinitis
  • retained sputum
  • skin laceration
  • rib fracture
  • ligament injuries
  • limb injuries
  • road traffic accidents
  • splenic injury
  • sternal fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery obstructive disease
  • anxiety

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best kept at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

White, oval-shaped film-coated tablet with a yellow tint and double convex sides.

Package unit

10 tablets/box (10 tablets/PTP×1), 60 tablets/box (10 tablets/PTP×6), 30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.